Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREASTIMMUNE02 pegfilgrastim impact on trastuzumab antitumor effect in HER2-positive operable breast cancer
2017-002069-22Phase 2Active
- Sponsor
- Centre Léon Bérard
- Start
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegfilgrastim in breast cancer (2 arms), sponsored by Centre Léon Bérard. Primary endpoint: Pathological complete response rate. Started Mar 2018; status: active.
02
Drugs
pegfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-002069-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002069-22.